China Approves Genuine Biotechs HIV Drug For COVID Patients

The Azvudine tablet, which China approved in July last year to treat certain HIV-1 virus infections, has been given a conditional green light to treat adult patients with "normal type" COVID, the National Medical Products Administration said in a statement. : China on Monday gave conditional approval to domestic firm Genuine Biotech's Azvudine pill to treat certain adult patients with COVID-19, adding another oral treatment option against the coronavirus. The availability of effective COVID vaccines and treatments is crucial in laying the groundwork for China's potential pivoting from its "dynamic COVID zero" policy, which aims to eliminate every outbreak - however small - and relies on mass testing and strict quarantining. The Azvudine tablet, which China approved in July last year to treat certain HIV-1 "Normal type" COVID is a term China uses to refer to coronavirus infections where there are signs of pneumonia, but the patients haven't reached a severe stage. China in February allowed the use of Pfizer's oral treatment Paxlovid in adults with mild-to-moderate COVID and high risk of progressing to a severe condition. In 2020, it approved the use of Lianhuaqingwen capsules, a traditional Chinese medicine-style formula, to alleviate symptoms of COVID such as fever and cough. In a late-stage clinical trial, 40.4% of patients taking Azvudine showed improvement in symptoms seven days after first taking the drug, compared with 10.9% in the control group, Henan province-based Genuine Biotech said in a statement earlier this month, without providing detailed readings. Other Chinese companies developing potential oral COVID treatments include Shanghai Junshi Biosciences and Kintor Pharmaceutical.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!